Hantavirus and Travel Health: Why There Is Still No Vaccine — and What Travellers Need to Know

As reports emerge of Canadians isolating after exposure linked to the hantavirus outbreak aboard the MV Hondius cruise ship, many travellers are understandably asking an important question: Is there a vaccine for hantavirus?

At this time, the answer is no. According to the World Health Organization (WHO), there is currently no licensed vaccine or specific antiviral treatment available for hantavirus infection. While researchers and biotechnology companies are actively working on vaccine development, experts caution that significant scientific and regulatory hurdles remain before a vaccine could become publicly available.

At Destinations Travel Clinic (DTC), our physician- and nurse-led travel medicine team believes travellers deserve clear, evidence-based guidance during emerging infectious disease events. Understanding hantavirus risk, how transmission occurs, and what protective measures matter most is essential for informed travel decisions.

What Is Hantavirus?

Hantaviruses are a family of viruses primarily spread through contact with infected rodents or their bodily fluids, including urine, droppings, and saliva. In rare cases, some strains can spread between humans under specific circumstances.

Different hantavirus strains exist worldwide, and illness severity varies depending on the strain involved. Certain forms can cause:

• Hantavirus Pulmonary Syndrome (HPS) — a severe respiratory illness 
• Hemorrhagic Fever with Renal Syndrome (HFRS) — which primarily affects the kidneys 

Symptoms may initially resemble influenza or other viral infections, including:

• Fever 
• Fatigue 
• Muscle aches 
• Headache 
• Nausea 
• Cough or shortness of breath 

In severe cases, respiratory failure can occur rapidly.

Why Is the Current Cruise Ship Outbreak Receiving Attention?

The outbreak aboard the MV Hondius has drawn international attention after multiple confirmed and suspected cases were identified, including several deaths. Public health authorities are closely monitoring exposed travellers, including Canadians currently isolating after potential exposure.

However, experts continue to emphasize several important facts:

• The overall public risk remains low 
• Hantavirus is very different from COVID-19 
• Sustained widespread community transmission is not currently expected 
• Most transmission requires close and prolonged exposure 

Health Canada has stated that the risk to the general Canadian population remains low, and the WHO has reported no evidence of broader uncontrolled spread at this time.

Why Don’t We Already Have a Hantavirus Vaccine?

Developing vaccines against rare or geographically limited viruses is scientifically and financially complex. Unlike influenza or COVID-19, hantavirus outbreaks are relatively infrequent and involve multiple viral strains, making vaccine design more challenging.

Several vaccine approaches are currently being explored internationally, including:

• mRNA vaccine platforms 
• Traditional viral protein vaccines 
• Experimental DNA vaccine technologies 

Pharmaceutical companies such as Moderna are investigating mRNA-based hantavirus vaccine candidates in collaboration with research institutions and military infectious disease programs. However, these remain in early development stages.

Before any vaccine becomes publicly available, it must undergo:

1. Laboratory development 
2. Animal testing 
3. Phase 1 human safety trials 
4. Phase 2 immune response studies 
5. Large-scale Phase 3 efficacy trials 
6. Regulatory review and approval 

This process can take years, even when accelerated.

Lessons Learned From COVID-19

Many infectious disease specialists note that the current hantavirus discussion highlights the importance of sustained investment in public health research and vaccine science.

The rapid development of COVID-19 vaccines was possible because of decades of prior research into:

• mRNA technology 
• coronavirus biology 
• global vaccine infrastructure 
• emergency clinical trial systems 

Hantavirus research remains far earlier in its development cycle. While modern vaccine technology offers hope, experts caution against expecting an immediate vaccine solution during the current outbreak.

How Travellers Can Reduce Their Risk

Because no vaccine currently exists, prevention relies heavily on exposure reduction and travel health awareness.

At DTC, our travel medicine physicians and nurses advise travellers to take precautions when travelling to regions where hantavirus exposure may occur.

Recommended Prevention Strategies

Avoid Rodent Exposure

• Do not touch rodents, nests, or droppings 
• Avoid sleeping in poorly ventilated cabins, sheds, or structures with rodent activity 
• Keep food sealed and stored properly 

Practice Environmental Awareness

• Avoid sweeping enclosed dusty areas that may aerosolize contaminated particles 
• Use appropriate cleaning precautions in high-risk environments 

Monitor Symptoms After Travel

Travellers who develop fever, cough, shortness of breath, or flu-like symptoms after potential exposure should seek medical attention promptly and disclose their travel history.

Seek Pre-Travel Medical Consultation

Travellers embarking on:

• Expedition cruises 
• Remote ecotourism trips 
• Adventure travel 
• Rural or wilderness travel 

should consider a professional travel health consultation before departure.

Why Professional Travel Health Advice Matters

Emerging infectious disease events evolve quickly. Online information is often incomplete, alarmist, or outdated.

At Destinations Travel Clinic (DTC), our travel health consultations are led primarily by physicians and nurses specializing in travel medicine, with support from trained travel health pharmacists. We provide:

• Destination-specific risk assessments 
• Personalized prevention planning 
• Vaccine recommendations 
• Cruise travel counselling 
• Expedition travel guidance 
• Post-travel illness assessment support 

Our goal is to help travellers make informed, evidence-based decisions while avoiding unnecessary panic.

Key Takeaways

• There is currently no approved hantavirus vaccine 
• Experimental vaccine research is ongoing internationally 
• Current public risk in Canada remains low 
• Prevention focuses on minimizing rodent exposure 
• Cruise and expedition travellers should remain informed but not alarmed 
• Professional pre-travel medical counselling remains one of the best tools for reducing infectious disease risk abroad 

For travellers planning cruises, wilderness travel, or international expeditions, a travel health consultation can help clarify risks and appropriate preventive measures before departure.

The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your health care provider first. Full Disclaimer